Technical Analysis for ATNF - 180 Life Sciences Corp.

Grade Last Price % Change Price Change
F 2.37 1.28% 0.03
ATNF closed up 1.28 percent on Thursday, November 21, 2024, on 2 percent of normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Flat Down Down

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Resistance Bearish 1.28%
NR7 Range Contraction 1.28%
NR7-2 Range Contraction 1.28%
Narrow Range Bar Range Contraction 1.28%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 6 hours ago
Rose Above Previous Day's High about 6 hours ago
200 DMA Resistance about 6 hours ago
Outside Day about 6 hours ago
Down 5% about 6 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease – inflammation. The Company is driving groundbreaking study into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The Company’s primary platform is a novel program to treat fibrosis using anti-TNF, with its lead program in phase 2b/3 clinical trials.
Classification

Sector: Industrials
Industry: Conglomerates
Keywords: Biotechnology Clinical Medicine Disease Immunology Pain Inflammation Inflammatory Diseases Cytokine Fibrosis Human Physiology Tumor Necrosis Factor Animal Physiology

Is ATNF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.75
52 Week Low 1.16
Average Volume 2,509,677
200-Day Moving Average 2.38
50-Day Moving Average 2.70
20-Day Moving Average 3.18
10-Day Moving Average 2.66
Average True Range 0.60
RSI (14) 41.18
ADX 44.47
+DI 45.64
-DI 21.85
Chandelier Exit (Long, 3 ATRs) 4.10
Chandelier Exit (Short, 3 ATRs) 4.02
Upper Bollinger Bands 4.54
Lower Bollinger Band 1.83
Percent B (%b) 0.2
BandWidth 84.90
MACD Line -0.19
MACD Signal Line -0.03
MACD Histogram -0.16
Fundamentals Value
Market Cap 24.08 Million
Num Shares 10.2 Million
EPS -14.20
Price-to-Earnings (P/E) Ratio -0.17
Price-to-Sales 0.00
Price-to-Book 0.36
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.64
Resistance 3 (R3) 2.64 2.54 2.60
Resistance 2 (R2) 2.54 2.47 2.55 2.58
Resistance 1 (R1) 2.46 2.43 2.50 2.46 2.57
Pivot Point 2.36 2.36 2.38 2.36 2.36
Support 1 (S1) 2.28 2.29 2.32 2.28 2.17
Support 2 (S2) 2.18 2.25 2.18 2.16
Support 3 (S3) 2.10 2.18 2.14
Support 4 (S4) 2.10